IBI362 + IBI362 placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adolescents With Obesity
Conditions
Adolescents With Obesity
Trial Timeline
Aug 30, 2024 → Aug 1, 2025
NCT ID
NCT06536023About IBI362 + IBI362 placebo
IBI362 + IBI362 placebo is a phase 1 stage product being developed by Innovent Biologics for Adolescents With Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT06536023. Target conditions include Adolescents With Obesity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06536023 | Phase 1 | Completed |
Competing Products
3 competing products in Adolescents With Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorcaserin | Eisai | Phase 1 | 33 |
| Placebo + IBI362 | Innovent Biologics | Phase 3 | 76 |
| rizatriptan benzoate | Organon | Phase 3 | 72 |